Adial Pharmaceuticals (ADIL) Liabilities and Shareholders Equity (2017 - 2026)

Adial Pharmaceuticals has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $5.2 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 51.47% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.4 million (up 20.87% YoY) and the FY2025 annual result came in at $6.7 million, up 32.3% from the prior year.
• Liabilities and Shareholders Equity slipped to $5.2 million in Q1 2026 per ADIL's latest filing, from $6.7 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $14.0 million in Q1 2022 and troughed at $2.9 million in Q3 2023.
• A 5-year average of $6.2 million and a median of $5.7 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity tumbled 72.06% in 2023, then surged 134.1% in 2024.
• Over 5 years, Liabilities and Shareholders Equity stood at $5.7 million in 2022, then fell by 17.38% to $4.7 million in 2023, then advanced by 6.49% to $5.0 million in 2024, then jumped by 32.3% to $6.7 million in 2025, then fell by 21.67% to $5.2 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $5.2 million, $6.7 million, and $5.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.